Cardiol Therapeutics (CRDL) Free Cash Flow (2020 - 2026)

Cardiol Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 9.44% year-over-year to -$5.4 million; the trailing twelve-month figure through Mar 2026 stood at -$17.5 million (up 3.57% YoY), and the FY2025 full-year result was -$17.1 million, up 4.63% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$5.4 million, down from -$3.8 million in the prior quarter.
• The five-year high for Free Cash Flow was -$1.3 million in Q3 2022, with the low at -$9.3 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$4.7 million across 5 years, with a median of -$4.8 million in 2023.
• The largest YoY upside for Free Cash Flow was 74.57% in 2022 against a maximum downside of 191.99% in 2022.
• Cardiol Therapeutics' Free Cash Flow stood at -$9.3 million in 2022, then surged by 48.1% to -$4.8 million in 2023, then climbed by 16.65% to -$4.0 million in 2024, then grew by 6.21% to -$3.8 million in 2025, then plunged by 44.11% to -$5.4 million in 2026.
• The last three Free Cash Flow figures came in at -$5.4 million (Q1 2026), -$3.8 million (Q4 2025), and -$5.0 million (Q3 2025), per Business Quant data.